Phospho-GRIN1 (Ser890) Antibody

What is the biological significance of GRIN1 Ser890 phosphorylation?

The phosphorylation of GRIN1 (also known as GluN1 or NR1) at Serine 890 plays a critical role in regulating NMDA receptor trafficking and function. This post-translational modification is primarily mediated by Protein Kinase C (PKC) and significantly influences receptor localization and channel properties. Phosphorylation at Ser890 is particularly important for activity-dependent synaptic plasticity mechanisms underlying learning and memory formation .

NMDA receptors containing phosphorylated GluN1 at Ser890 exhibit distinct electrophysiological properties from their non-phosphorylated counterparts. Research shows that PKC-dependent phosphorylation at this site affects receptor clustering at synapses and contributes to the regulation of calcium influx through the NMDA receptor channel .

How does PKC mediate GRIN1 Ser890 phosphorylation?

PKC-dependent phosphorylation of GRIN1 at Ser890 occurs through a specific signaling cascade that can be experimentally triggered using phorbol esters such as PMA (phorbol 12-myristate 13-acetate). Recent research demonstrates that pharmacological PKC activation with PMA significantly increases phosphorylation of GluN1 at Ser890, and this effect can be blocked by the PKC inhibitor GF-109203X .

The phosphorylation mechanism appears to be independent of transcriptional regulation, suggesting a direct signaling pathway at synapses. Notably, CRTC1 (CREB-regulated transcription coactivator 1) has been identified as a critical regulator of PKC-dependent GRIN1 Ser890 phosphorylation, with CRTC1 overexpression increasing phosphorylated GluN1 levels at Ser890 .

What applications are recommended for Phospho-GRIN1 (Ser890) antibodies?

Phospho-GRIN1 (Ser890) antibodies are validated for multiple experimental applications, including:

• ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative detection of phosphorylated GRIN1 in tissue lysates and cellular extracts

• IHC (Immunohistochemistry): Recommended dilution range of 1:50-1:100 for tissue sections

• IF (Immunofluorescence): Recommended dilution range of 1:100-1:200 for cellular imaging

These antibodies can be effectively used in studies investigating neuronal signaling, synaptic plasticity, and neurodevelopmental disorders where NMDA receptor function may be altered.

What is the species reactivity profile of Phospho-GRIN1 (Ser890) antibodies?

Commercial Phospho-GRIN1 (Ser890) antibodies typically demonstrate reactivity across multiple species, including:

• Human

• Mouse

• Rat

This cross-species reactivity makes these antibodies versatile tools for comparative studies across different model systems. When selecting an antibody, researchers should verify the specific reactivity profile of their chosen product, as some antibodies may show differential affinity across species.

How does phosphorylation at Ser890 differ from other GRIN1 phosphorylation sites?

GRIN1 contains multiple phosphorylation sites that are regulated by different kinases and serve distinct functions:

While Ser890 and Ser896 are both phosphorylated by PKC, they have distinct roles in NMDA receptor regulation. Experimental evidence shows that CRTC1 overexpression increases phosphorylation at both Ser890 and Ser897 sites, suggesting potential crosstalk between these regulatory mechanisms .

How does CRTC1 regulate GluN1 (Ser890) phosphorylation in synaptic plasticity?

Recent research has revealed that CRTC1 plays a crucial role in maintaining both levels and PKC-dependent phosphorylation of GluN1 at Ser890 in the adult hippocampus. Biochemical analyses demonstrate that CRTC1 overexpression significantly increases phosphorylated GluN1 at Ser890, while CRTC1 silencing reduces both total and surface GluN1 levels .

A particularly significant finding is that CRTC1's regulation of GluN1 phosphorylation appears to operate through two distinct mechanisms:

• Transcription-independent pathway: Activity-dependent GluN1 phosphorylation at Ser890 does not require gene transcription, as demonstrated by experiments with actinomycin D (ActD)

• Local synaptodendritic effects: A phosphorylation-deficient CRTC1 mutant that fails to induce CRE-transcriptional activity can still increase the number of PSD95 puncta and GluN1/PSD95 colocalization in basal conditions

These findings suggest that CRTC1 mediates local signaling mechanisms at synapses that are independent of its well-established nuclear transcriptional regulatory role.

What are the optimal protocols for detecting Phospho-GRIN1 (Ser890) in different neural preparations?

For Tissue Sections (IHC/IF):

• Fix tissue in 4% paraformaldehyde for 24 hours

• Prepare sections (10-20 μm thickness optimal for neuronal tissue)

• Block with 5% normal serum and 0.1% Triton X-100

• Incubate with Phospho-GRIN1 (Ser890) antibody at 1:50-1:100 dilution for IHC or 1:100-1:200 for IF

• For IF, use appropriate fluorophore-conjugated secondary antibodies

• Include positive controls (tissues known to express phosphorylated GRIN1) and negative controls (omitting primary antibody)

For Primary Neuronal Cultures:

• Culture hippocampal neurons for 14-21 DIV to allow mature synapse formation

• Fix cells in 4% paraformaldehyde for 15 minutes

• Permeabilize with 0.1% Triton X-100

• Block with 5% BSA

• Incubate with Phospho-GRIN1 (Ser890) antibody at 1:100-1:200 dilution

• Co-stain with synaptic markers such as PSD95 to analyze synaptic localization

For Biochemical Assays:

• For optimal results in biochemical analyses, rapidly dissect and flash-freeze tissues

• Homogenize in buffer containing phosphatase inhibitors to preserve phosphorylation state

• For surface expression studies, consider biotinylation assays as demonstrated in the literature with GluN1

How can you validate the specificity of Phospho-GRIN1 (Ser890) antibodies?

To ensure experimental rigor, multiple validation approaches should be employed:

• Phosphatase Treatment Control: Treat half of your sample with lambda phosphatase to remove phosphorylation - a specific phospho-antibody should show diminished signal

• Peptide Competition Assay: Pre-incubate antibody with phosphorylated and non-phosphorylated peptides containing the Ser890 sequence (A-S-S(p)-F-K) - signal should be blocked only by the phospho-peptide

• PKC Modulators: Treat samples with PKC activators (PMA) and inhibitors (GF-109203X) - specific antibodies should show corresponding changes in signal intensity

• Knockout/Knockdown Controls: When possible, use genetic models where GRIN1 is absent or reduced to confirm antibody specificity

• Cross-Validation: Compare results using multiple antibodies targeting the same phosphorylation site from different suppliers or using different detection methods

What are the implications of altered GRIN1 Ser890 phosphorylation in neurological disorders?

Dysregulation of GRIN1 phosphorylation has been linked to several neurological conditions:

• Neurodevelopmental Disorders: GRIN1 mutations have been identified in patients with polymicrogyria and epileptic encephalopathy. While these mutations primarily affect receptor function through other mechanisms, alterations in phosphorylation-dependent regulation may contribute to pathology

• Synaptic Dysfunction: Since PKC-dependent GluN1 phosphorylation regulates synaptic potentiation, abnormal phosphorylation patterns may underlie synaptic deficits observed in conditions like schizophrenia and Alzheimer's disease

• Excitotoxicity: NMDA receptor-mediated excitotoxicity is influenced by receptor trafficking and surface expression, which are regulated by Ser890 phosphorylation. This suggests potential therapeutic approaches targeting this phosphorylation site

• Learning and Memory Disorders: The involvement of CRTC1-mediated GluN1 phosphorylation in synaptic plasticity indicates that disruptions to this pathway could contribute to cognitive impairments

Research examining phosphorylation-state specific changes in these disorders remains an active and promising field that could identify novel therapeutic targets.

How do you troubleshoot inconsistent results when using Phospho-GRIN1 (Ser890) antibodies?

When encountering variability in phospho-GRIN1 detection, consider these methodological approaches:

• Sample Preparation Issues:

  • Ensure rapid tissue processing to prevent phosphorylation loss

  • Include comprehensive phosphatase inhibitor cocktails in all buffers

  • Maintain samples at 4°C throughout processing

• Antibody-Specific Considerations:

  • Optimize antibody concentration through titration experiments

  • Test different blocking reagents to reduce background

  • Consider lot-to-lot variability by validating each new antibody lot

• Biological Variability:

  • Control for circadian fluctuations in phosphorylation levels

  • Account for region-specific differences in neural tissues

  • Consider activity-dependent changes that might influence results

• Technical Controls:

  • Include phosphorylation-positive controls (e.g., PMA-treated samples)

  • Run phosphorylation-negative controls (e.g., phosphatase-treated samples)

  • Normalize phospho-signal to total GRIN1 expression

What are the best approaches for quantifying changes in GRIN1 Ser890 phosphorylation?

For robust quantification of GRIN1 Ser890 phosphorylation:

• Western Blot Analysis:

  • Always run parallel blots for total GRIN1 and phospho-GRIN1

  • Calculate the phospho-GRIN1/total GRIN1 ratio to control for expression differences

  • Include gradient standard curves to ensure measurements in the linear range

• ELISA-Based Quantification:

  • Commercial ELISA kits provide high sensitivity detection

  • Consider sandwich ELISA approaches using anti-GRIN1 capture and anti-phospho-Ser890 detection antibodies

• Imaging-Based Approaches:

  • For cellular/tissue imaging, use consistent acquisition parameters

  • Quantify phospho-GRIN1 colocalization with synaptic markers like PSD95

  • Consider super-resolution microscopy for precise synaptic localization studies

• In situ Proximity Ligation Assay (PLA):

  • Offers highly sensitive detection of phosphorylation events

  • Can be combined with other markers to assess compartment-specific changes

Emerging research directions

Future studies on GRIN1 Ser890 phosphorylation are likely to focus on:

• Single-cell resolution phosphorylation dynamics during synaptic plasticity

• Development of phosphorylation state-specific modulators as potential therapeutics

• Further elucidation of the CRTC1-dependent regulation of GRIN1 phosphorylation

• Investigation of cross-talk between different GRIN1 phosphorylation sites

• Characterization of phosphorylation patterns in patient-derived samples to identify disease-specific signatures